Benzinga - by Avi Kapoor, Benzinga Staff Writer.
Shares of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) rose sharply in today’s pre-market trading session.
Titan Pharmaceuticals said its Board of Directors has approved a 1-for-20 reverse stock split.
Titan Pharmaceuticals shares jumped 15.2% to $0.38 in pre-market trading.
Here are some other stocks moving in pre-market trading.
Gainers
- China Green Agriculture, Inc. (NYSE: CGA) shares gained 173.2% to $5.19 in pre-market trading. On Dec. 27, China Green Agriculture entered into a stock purchase agreement with Zhibiao Pan for the acquisition of all outstanding stock of Lonestar Dream for a total consideration of $49 million.
- FLJ Group Limited(NASDAQ: FLJ) gained 94.8% to $2.63 in pre-market trading. FLJ Group completed $180 million cash purchase of Alpha Mind Technology and terminated equity acquisition agreement entered into with Lianlian Holdings Inc.
- Kintara Therapeutics, Inc. (NASDAQ: KTRA) rose 71% to $0.33 in pre-market trading after gaining 7% on Thursday.
- cbdMD, Inc. (NYSE: YCBD) shares rose 27.8% to $1.01 in pre-market trading after gaining 11% on Thursday.
- CN Energy Group. Inc. (NASDAQ: CNEY) shares gained 19.7% to $0.0720 in pre-market trading after gaining around 20% on Thursday.
- Green Giant Inc. (NASDAQ: GGE) shares rose 14% to $0.0595 in pre-market trading. Green Giant recently announced pricing of public offering.
- Genius Group Limited (NYSE: GNS) shares gained 11.4% to $0.7686 in pre-market trading. Genius Group recently updated financial guidance for the financial year ending December 31, 2023.
- Dunxin Financial Holdings Limited (NYSE: DXF) gained 11.3% to $0.38 in pre-market trading.
- Visionary Education Technology Holdings Group Inc. (NASDAQ: GV) shares climbed 10.2% to $0.23 in pre-market trading.
- flyExclusive Inc (NYSE: FLYX) shares fell 24.1% to $5.20 in pre-market trading after dipping over 42% on Thursday.
- Cingulate Inc. (NASDAQ: CING) shares fell 23.1% to $7.55 in pre-market trading. Cingulate shares jumped 146% on Thursday after the company announced it received guidance from the FDA regarding its clinical program for CTx-1301.
- SenesTech, Inc. (NASDAQ: SNES) shares fell 23.1% to $1.33 in pre-market trading after jumping over 100% on Thursday. Earlier in December SenesTech announced substantial initial orders for its Evolve Soft Bait product which controls pests through a nontoxic method of fertility control. The company also announced its entry into an exclusive distribution agreement with Fruit Tree Limited, a pest control company based in Hong Kong.
- Banyan Acquisition Corporation (NYSE: BYN) shares fell 20.8% to $10.25 in pre-market trading after jumping 42% on Thursday.
- Nova LifeStyle, Inc. (NASDAQ: NVFY) fell 18.2% to $3.84 in pre-market trading after jumping 203% on Thursday.
- Sidus Space, Inc. (NASDAQ: SIDU) shares fell 17.3% to $9.51 in pre-market trading. Sidus Space shares surged 163% on Thursday amid increased volatility after the company highlighted its 2023 achievements which it says have laid the groundwork for an anticipated launch in Q1 2024.
- Ucommune International Ltd (NASDAQ: UK) shares fell 17.2% to $4.30 in pre-market trading after jumping over 71% on Thursday. Ucommune recently regained compliance with Nasdaq minimum bid price requirement.
- Asset Entities Inc. (NASDAQ: ASST) shares fell 14.4% to $0.5315 in pre-market trading after adding around 5% on Thursday.
- Bone Biologics Corporation (NASDAQ: BBLG) shares fell 13.5% to $5.19 in pre-market trading after gaining 29% on Thursday. Bone Biologics' stock recently effected a 1-for-8 reverse-split on Dec. 20, and the company also announced the closing of a direct offering of 1,139,063 shares of common stock at a purchase price of $0.64 per share on Nov. 20.
- DatChat, Inc. (NASDAQ: DATS) fell 12.4% to $2.88 in pre-market trading. On Dec. 27, 2023, Datchat filed a certificate of change in Nevada to increase its authorized common stock from 18 million to 180 million shares.
Now Read This: Top 4 Utilities Stocks That Could Sink Your Portfolio In December
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.